Pharmacological inhibition of TSP-1 decreases glioblastoma cell proliferation and network synchrony within the tumour microenvironment, highlighting a potential therapeutic strategy to be assessed in future clinical studies. The gene discussed is THBS1; the disease is neoplasm.